Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1Biologic DMARD----2件: 46, 271
2Biologic DMARDs----1件: 107
3Biological DMARDs----2件: 86, 107
4Classic DMARDs treatment group----1件: 46
5Co-medication: Synthetic DMARDs----1件: 46
6Combination of DMARDs----1件: 107
7Conventional DMARD combination----1件: 46
8Conventional DMARDs----1件: 46
9Conventional Synthetic DMARD----1件: 46
10Disease-modifying antirheumatic drugs (DMARDs)----1件: 46
11DMARD----1件: 46
12DMARD cessation----1件: 46
13DMARD maintenance----1件: 46
14DMARD Therapy----1件: 46
15DMARDS----2件: 46, 271
16DMARDs (disease-modifying antirheumatic drugs)----1件: 46
17DMARDs (methotrexate1件: Methotrexate1件: D00142 2件: DHFR,
DHFR2 💬		5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬1件: 46
18DMARDs or Biologics----1件: 46
19Etanercept, other Biologics, Disease-modifying antirheumatic drugs (DMARDs), etc1件: Etanercept1件: D00742 2件: LTA,
TNF 💬		67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 46
20HUC-MSC + DMARDs----1件: 46
21Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)----1件: 46
22Non-Biologic DMARDs----3件: 46, 86, 107
23Non-biological DMARDs----1件: 46
24Nonbiologic DMARDs of investigator's choice----1件: 46
25Patient treated with DMARD----1件: 46
26Permitted DMARDs----1件: 46
27Phase 1: Conventiaonal DMARD----1件: 46
28Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs)----1件: 46
29Standard DMARDs (Disease Modifying Anti Rheumatic Drugs)----1件: 46
30Synthetic DMARD(s)----1件: 46
31Targeted synthetic DMARD class----1件: 46
32Therapy with disease-modifying anti rheumatic drugs (DMARD)----1件: 46
33TNF-a antagonists, non-TNFs, DMARD non-biologics----2件: 46, 271
34Trivalent chromium versus synthetic and/ or biological DMARDs1件: Chromium---1件: 46
35UC-MSC+DMARDS----1件: 46